TFF Pharmaceuticals, Inc. (NASDAQ:TFFP) Sees Large Decrease in Short Interest

TFF Pharmaceuticals, Inc. (NASDAQ:TFFP) was the recipient of a significant drop in short interest in the month of April. As of April 15th, there was short interest totalling 69,700 shares, a drop of 19.5% from the March 31st total of 86,600 shares. Based on an average trading volume of 31,200 shares, the short-interest ratio is presently 2.2 days. Currently, 2.8% of the shares of the company are sold short.

Analyst Upgrades and Downgrades

Separately, Roth Mkm dropped their target price on TFF Pharmaceuticals from $56.00 to $44.00 and set a “buy” rating on the stock in a report on Thursday, March 28th.

TFF Pharmaceuticals Stock Down 4.2 %

Shares of TFFP stock opened at $2.92 on Friday. The stock has a 50 day simple moving average of $5.86 and a 200-day simple moving average of $6.63. TFF Pharmaceuticals has a 1-year low of $2.51 and a 1-year high of $21.25.

TFF Pharmaceuticals (NASDAQ:TFFP) last announced its earnings results on Thursday, March 28th. The company reported ($2.01) earnings per share for the quarter, missing the consensus estimate of ($2.00) by ($0.01). The business had revenue of $0.11 million for the quarter, compared to analyst estimates of $0.20 million. TFF Pharmaceuticals had a negative return on equity of 163.14% and a negative net margin of 2,897.95%. Analysts expect that TFF Pharmaceuticals will post -7.28 EPS for the current year.

Institutional Inflows and Outflows

Large investors have recently made changes to their positions in the business. Westside Investment Management Inc. raised its stake in shares of TFF Pharmaceuticals by 382.1% during the 1st quarter. Westside Investment Management Inc. now owns 39,225 shares of the company’s stock worth $237,000 after buying an additional 31,089 shares during the period. Worth Venture Partners LLC raised its stake in TFF Pharmaceuticals by 66.2% in the 3rd quarter. Worth Venture Partners LLC now owns 646,832 shares of the company’s stock valued at $226,000 after purchasing an additional 257,722 shares during the last quarter. Finally, AIGH Capital Management LLC raised its stake in TFF Pharmaceuticals by 70.7% in the 3rd quarter. AIGH Capital Management LLC now owns 2,655,235 shares of the company’s stock valued at $929,000 after purchasing an additional 1,099,709 shares during the last quarter. 15.25% of the stock is owned by institutional investors and hedge funds.

TFF Pharmaceuticals Company Profile

TFF Pharmaceuticals, Inc, a clinical stage biopharmaceutical company, focuses on developing and commercializing drug products based on its patented Thin Film Freezing (TFF) technology platform in the United States and Australia. It intends to focus on the development of inhaled dry powder drugs for the treatment of pulmonary diseases and conditions.